Professor Tim Palmer Tim.Palmer@hull.ac.uk
HYMS Professor of Cardiovascular Biology
SOCS VASC - Stabilising suppressor of cytokine signalling 3 (SOCS3) to limit vascular re-modelling in vein graft failure and in-stent restenosis
People Involved
Dr James Hobkirk J.Hobkirk@hull.ac.uk
Lecturer in Physiology & Pathophysiology & Honorary Medical Scientist
Status | Project Complete |
---|---|
Funder(s) | Hull & East Riding Cardiac Trust Fund |
Value | £39,323.00 |
Project Dates | Dec 1, 2019 - May 31, 2022 |
Partner Organisations | 00 No Partners |
You might also like
Digital delivery of lifestyle behaviour change in patients requiring cardiac surgery? A scoping exercise focusing on patients and healthcare professionals Sep 12, 2022 - Jan 24, 2024
Patients who have undergone coronary artery bypass graft (CABG) benefit from cardiac rehabilitation (Class 1, Level A evidence). CR is recommended by the WHO, NICE and the NHS. Pre and post operative lifestyle was a high priority, as independently ju...
Read More about Digital delivery of lifestyle behaviour change in patients requiring cardiac surgery? A scoping exercise focusing on patients and healthcare professionals.
PreclinHUPET2: Enabling Enhanced Preclinical Nuclear Imaging For The North Of England Feb 1, 2023 - Jan 31, 2024
The grant application is to upgrade the preclinical scanning facilities for nuclear imaging of small animals (mice and rats) at the University of Hull. These facilities are used for research into disease and human health. The main areas that will be...
Read More about PreclinHUPET2: Enabling Enhanced Preclinical Nuclear Imaging For The North Of England.
FHS KE Pump Primer Award Mar 1, 2022 - Jul 31, 2022
Wolfson Equipment bid 2023 - Confocal Imaging ZEISS Elyra 7 with Lattice SIM² Oct 1, 2024 - Sep 30, 2029
: A Targeted Approach To Reduce Risk of Blood Clotting in MPN Patients Oct 1, 2023 - Jan 31, 2025
A new mechanism has been identified where an intracellular switch, called AMP-activated protein kinase (AMPK) inhibits the function of constitutively active JAK2V617F protein responsible for disease in many patients with MPNs. Based on this observati...
Read More about : A Targeted Approach To Reduce Risk of Blood Clotting in MPN Patients.